Top-Rated StocksTop-RatedNASDAQ:DYN Dyne Therapeutics (DYN) Stock Price, News & Analysis $36.41 +2.07 (+6.03%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Dyne Therapeutics alerts: Email Address About Dyne Therapeutics Stock (NASDAQ:DYN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Dyne Therapeutics alerts:Sign Up Key Stats Today's Range$34.87▼$37.0850-Day Range$31.94▼$47.0452-Week Range$6.40▼$47.45Volume2.43 million shsAverage Volume1.60 million shsMarket Capitalization$3.18 billionP/E RatioN/ADividend YieldN/APrice Target$51.40Consensus RatingBuy Company OverviewDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Read More… Kamala’s Dirty Election Move… Revealed (Ad)According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. Dyne Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 81st PercentileDyne Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 224th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingDyne Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDyne Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dyne Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dyne Therapeutics are expected to decrease in the coming year, from ($2.96) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dyne Therapeutics is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dyne Therapeutics is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDyne Therapeutics has a P/B Ratio of 24.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dyne Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.86% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDyne Therapeutics does not currently pay a dividend.Dividend GrowthDyne Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.86% of the outstanding shares of Dyne Therapeutics have been sold short.Short Interest Ratio / Days to CoverDyne Therapeutics has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Dyne Therapeutics has recently decreased by 6.91%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.14 News SentimentDyne Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Dyne Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for DYN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Dyne Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership5.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dyne Therapeutics insiders have sold 73.99% more of their company's stock than they have bought. Specifically, they have bought $1,057,280.00 in company stock and sold $1,839,603.00 in company stock.Percentage Held by Insiders20.77% of the stock of Dyne Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.68% of the stock of Dyne Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dyne Therapeutics' insider trading history. Receive DYN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Stock News HeadlinesInsider Buying: Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO Purchases 32,000 Shares of StockSeptember 5, 2024 | insidertrades.comShort Interest in Dyne Therapeutics, Inc. (NASDAQ:DYN) Drops By 6.9%September 20 at 3:11 AM | americanbankingnews.comNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall Street veteran, who served more than 50 years alongside the likes of Paul Tudor Jones and George Soros, just announced: "This is only the beginning."September 20, 2024 | Chaikin Analytics (Ad)Prilenia Appoints Rob Lauzen as Chief Financial Officer and Jason Marks as Chief Legal OfficerSeptember 19 at 4:37 PM | finance.yahoo.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc. - DYNSeptember 17 at 6:35 PM | prnewswire.com2 Breakout Biotech Stocks With CEO Insider BuyingSeptember 17 at 5:23 PM | msn.comDYN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Dyne Therapeutics, Inc. and Encourages Investors to Contact the Firm!September 17 at 4:00 PM | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Downgraded by StockNews.com to SellSeptember 17 at 5:59 AM | americanbankingnews.comSee More Headlines DYN Stock Analysis - Frequently Asked Questions How have DYN shares performed this year? Dyne Therapeutics' stock was trading at $13.30 on January 1st, 2024. Since then, DYN shares have increased by 173.8% and is now trading at $36.41. View the best growth stocks for 2024 here. How were Dyne Therapeutics' earnings last quarter? Dyne Therapeutics, Inc. (NASDAQ:DYN) released its quarterly earnings data on Monday, August, 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.02. When did Dyne Therapeutics IPO? Dyne Therapeutics (DYN) raised $175 million in an IPO on Thursday, September 17th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. JPMorgan, Jefferies, Piper Sandler and Stifel acted as the underwriters for the IPO. Who are Dyne Therapeutics' major shareholders? Dyne Therapeutics' top institutional investors include Sofinnova Investments Inc. (1.86%), Federated Hermes Inc. (1.39%), Armistice Capital LLC (1.11%) and Candriam S.C.A. (0.61%). Insiders that own company stock include Dirk Kersten, Venture Fund Xi LP Atlas, Joshua T Brumm, Wildon Farwell, Jonathan Mcneill, Oxana Beskrovnaya, Susanna Gatti High, Richard William Scalzo and John Cox. View institutional ownership trends. How do I buy shares of Dyne Therapeutics? Shares of DYN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/12/2024Today9/19/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DYN Previous SymbolNYSE:DYN CUSIPN/A CIK1818794 Webwww.dyne-tx.com Phone781-786-8230Fax781-786-8866Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$51.40 High Stock Price Target$66.00 Low Stock Price Target$42.00 Potential Upside/Downside+41.2%Consensus RatingBuy Rating Score (0-4)3.10 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-68.85% Return on Assets-59.96% Debt Debt-to-Equity RatioN/A Current Ratio26.63 Quick Ratio26.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.49 per share Price / Book24.44Miscellaneous Outstanding Shares87,383,000Free Float69,234,000Market Cap$3.18 billion OptionableOptionable Beta1.07 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:DYN) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersAct by Friday, August 16th, to collect this 22% dividendLet's do a little math here... To double your money at a 3% rate of return, you would need around 23 years....Investors Alley | SponsoredWhy You Should NOT Trade This MarketYou'll be interested in our 5-Day Options Trading Challenge, starting September 23. So, what makes this dif...InvestorPlace | SponsoredThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredNew September Stock WarningSeptember is the most volatile month of the year for stocks. And after the brutal tech selloff, one Wall St...Chaikin Analytics | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.